231 related articles for article (PubMed ID: 33361862)
1. IRIDIUM-192 RADIOTHERAPY BENEFITS IN THE MANAGEMENT OF GYNECOLOGICAL TUMORS.
Ivankova VS; Domina EA; Khrulenko TV; Baranovska LM; Hrinchenko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():569-578. PubMed ID: 33361862
[TBL] [Abstract][Full Text] [Related]
2. CONTEMPORARY APPROACHES TO PROGNOSTICATION AND MANAGEMENT OF PELVIC RADIATION INJURIES IN GYNECOLOGICAL CANCER PATIENTS.
Ivankova VS; Domina EA; Khrulenko TV; Baranovska LM; Glavin OA
Probl Radiac Med Radiobiol; 2022 Dec; 27():455-473. PubMed ID: 36582109
[TBL] [Abstract][Full Text] [Related]
3. Radiobiological and dosimetric comparison of 60Co versus 192Ir high-dose-rate intracavitary-interstitial brachytherapy for cervical cancer.
Wen A; Wang X; Wang B; Yan C; Luo J; Wang P; Li J
Radiat Oncol; 2022 Dec; 17(1):206. PubMed ID: 36514118
[TBL] [Abstract][Full Text] [Related]
4. Image-Guided Brachytherapy a Comparison Between 192Ir and 60Co Sources in Carcinoma Uterine Cervix.
Sinnatamby M; Kandasamy S; Karunanidhi G; Neelakandan V; Ramapandian S; Kannan M; Sampath E
Gulf J Oncolog; 2022 Jan; 1(38):7-14. PubMed ID: 35156639
[TBL] [Abstract][Full Text] [Related]
5. Study of encapsulated 170Tm sources for their potential use in brachytherapy.
Ballester F; Granero D; Perez-Calatayud J; Venselaar JL; Rivard MJ
Med Phys; 2010 Apr; 37(4):1629-37. PubMed ID: 20443484
[TBL] [Abstract][Full Text] [Related]
6. Monte Carlo calculations of the ionization chamber wall correction factors for 192Ir and 60Co gamma rays and 250 kV x-rays for use in calibration of 192Ir HDR brachytherapy sources.
Ferreira IH; de Almeida CE; Marre D; Marechal MH; Bridier A; Chavaudra J
Phys Med Biol; 1999 Aug; 44(8):1897-904. PubMed ID: 10473203
[TBL] [Abstract][Full Text] [Related]
7. Accuracy assessment of the superposition principle for evaluating dose distributions of elongated and curved 103Pd and 192Ir brachytherapy sources.
Bannon EA; Yang Y; Rivard MJ
Med Phys; 2011 Jun; 38(6):2957-63. PubMed ID: 21815369
[TBL] [Abstract][Full Text] [Related]
8. Effects of brachytherapy on cytogenetic parameters and oxidative status in peripheral blood lymphocytes of gynecologic cancer patients.
Ivankova VS; Domina EA; Khrulenko TV; Makovetska LI; Hrinchenko OO; Baranovska LM
Exp Oncol; 2021 Sep; 43(3):242-246. PubMed ID: 34591418
[TBL] [Abstract][Full Text] [Related]
9. Comparison of organ doses for patients undergoing balloon brachytherapy of the breast with HDR 192Ir or electronic sources using monte carlo simulations in a heterogeneous human phantom.
Mille MM; Xu XG; Rivard MJ
Med Phys; 2010 Feb; 37(2):662-71. PubMed ID: 20229875
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of intracavitary applicators in 192Ir-HDR brachytherapy.
Ye SJ; Brezovich IA; Shen S; Duan J; Popple RA; Pareek PN
Med Phys; 2004 Jul; 31(7):2097-106. PubMed ID: 15305463
[TBL] [Abstract][Full Text] [Related]
11. Absorbed dose determination at short distance from 60Co and 192Ir brachytherapy sources.
Tölli H; Johansson KA
Phys Med Biol; 1998 Nov; 43(11):3183-94. PubMed ID: 9832010
[TBL] [Abstract][Full Text] [Related]
12. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
13. Comparative Analysis of 60Co and 192Ir Sources in High Dose Rate Brachytherapy for Cervical Cancer.
Wen A; Wang X; Wang B; Yan C; Luo J; Wang P; Li J
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230672
[TBL] [Abstract][Full Text] [Related]
14. Direction modulated brachytherapy (DMBT) for treatment of cervical cancer: A planning study with
Safigholi H; Han DY; Mashouf S; Soliman A; Meigooni AS; Owrangi A; Song WY
Med Phys; 2017 Dec; 44(12):6538-6547. PubMed ID: 28940520
[TBL] [Abstract][Full Text] [Related]
15. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for implementation of high dose rate 192Ir brachytherapy in developing countries by the Advisory Group of International Atomic Energy Agency.
Nag S; Dally M; de la Torre M; Tatsuzaki H; Kizilbash N; Kurusun S; Pinillos L; Pokrajac B; Sur R; Levin V
Radiother Oncol; 2002 Sep; 64(3):297-308. PubMed ID: 12242118
[TBL] [Abstract][Full Text] [Related]
17. Response of an implantable MOSFET dosimeter to 192Ir HDR radiation.
Fagerstrom JM; Micka JA; DeWerd LA
Med Phys; 2008 Dec; 35(12):5729-37. PubMed ID: 19175130
[TBL] [Abstract][Full Text] [Related]
18. A feasibility study of Fricke dosimetry as an absorbed dose to water standard for 192Ir HDR sources.
deAlmeida CE; Ochoa R; Lima MC; David MG; Pires EJ; Peixoto JG; Salata C; Bernal MA
PLoS One; 2014; 9(12):e115155. PubMed ID: 25521914
[TBL] [Abstract][Full Text] [Related]
19. Determination of absorbed dose in water at the reference point d(r0, theta0) for an 192Ir HDR brachytherapy source using a Fricke system.
Austerlitz C; Mota HC; Sempau J; Benhabib SM; Campos D; Allison R; DeAlmeida CE; Zhu D; Sibata CH
Med Phys; 2008 Dec; 35(12):5360-5. PubMed ID: 19175095
[TBL] [Abstract][Full Text] [Related]
20. A dosimetric comparison of 169Yb and 192Ir for HDR brachytherapy of the breast, accounting for the effect of finite patient dimensions and tissue inhomogeneities.
Lymperopoulou G; Papagiannis P; Angelopoulos A; Karaiskos P; Georgiou E; Baltas D
Med Phys; 2006 Dec; 33(12):4583-9. PubMed ID: 17278810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
